REGENXBIO Inc. (Nasdaq: RGNX) today announced the closing of its Collaboration and License Agreement with AbbVie to develop and commercialize RGX-314, a potential one-time gene therapy for the treatment of wet age-related macular degeneration (wet AMD), diabetic retinopathy (DR) and other chronic retinal diseases.
REGENXBIO and Solid Biosciences Take Aim at Rare Diseases with AAV Gene Therapies via New Pathway Development Consortium
Rare disease specialist REGENXBIO is partnering with Solid Biosciences to advance AAV gene therapies for rare diseases through an accelerated approval pathway with the U.S. Food and Drug Administration.
Investors Eye Gene Therapy Companies and Rapidly Expanding Market – Five Publicly Traded Gene Therapy Companies
As some are now calling it, the greater Philadelphia region, or ‘Cellecon Valley, is garnering a lot of attention these days as a rapidly emerging Biopharma cluster, earning a defining spot among the top 10 clusters in the US.
At BioBuzz, we’ve written extensively about the promise of cell and gene therapeutics for both patients and the companies developing these revolutionary personalized medicines.
2020 was a year like no other for BioHealth Capital Region (BCHR) biotechs, and this year is expected to bring substantial growth across many sectors.
Duchenne Muscular Dystrophy is a severe degenerative muscle disease that impacts about one in 5,000 boys per year across the globe. The disease causes a progressive loss of muscle strength attributable to a loss of a protein called dystrophin, which normally protects muscle fibers from breaking down.
2020 found the United States embroiled in a chaotic political environment, reckoning with social unrest and racial injustice, and voting in one of the most consequential presidential elections in the country’s history.
The COVID-19 Pandemic didn’t stop the Maryland Tech Council from holding their 32nd Annual Industry awards. Taking this event online, MTC continued via a live virtual broadcast to recognize the top Life Sciences and Tech Companies in Maryland.
Maryland Biomanufacturing Leaders Discuss Challenges, Future Needs at 2020 Bio Innovation Conference
The BioHealth Capital Region (BHCR) is known globally as a leading vaccine hub with nearly 20% of the world’s leading vaccine development influencers in Maryland, which is the heart of the BHCR.